These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 20647475)

  • 1. Targeting cell division cycle 7 kinase: a new approach for cancer therapy.
    Montagnoli A; Moll J; Colotta F
    Clin Cancer Res; 2010 Sep; 16(18):4503-8. PubMed ID: 20647475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cdc7 as a potential new target for cancer therapy.
    Ito S; Taniyami C; Arai N; Masai H
    Drug News Perspect; 2008 Nov; 21(9):481-8. PubMed ID: 19180266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity.
    Montagnoli A; Valsasina B; Croci V; Menichincheri M; Rainoldi S; Marchesi V; Tibolla M; Tenca P; Brotherton D; Albanese C; Patton V; Alzani R; Ciavolella A; Sola F; Molinari A; Volpi D; Avanzi N; Fiorentini F; Cattoni M; Healy S; Ballinari D; Pesenti E; Isacchi A; Moll J; Bensimon A; Vanotti E; Santocanale C
    Nat Chem Biol; 2008 Jun; 4(6):357-65. PubMed ID: 18469809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cdc7 inhibition reveals a p53-dependent replication checkpoint that is defective in cancer cells.
    Montagnoli A; Tenca P; Sola F; Carpani D; Brotherton D; Albanese C; Santocanale C
    Cancer Res; 2004 Oct; 64(19):7110-6. PubMed ID: 15466207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cdc7 kinase - a new target for drug development.
    Swords R; Mahalingam D; O'Dwyer M; Santocanale C; Kelly K; Carew J; Giles F
    Eur J Cancer; 2010 Jan; 46(1):33-40. PubMed ID: 19815406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery.
    Menichincheri M; Bargiotti A; Berthelsen J; Bertrand JA; Bossi R; Ciavolella A; Cirla A; Cristiani C; Croci V; D'Alessio R; Fasolini M; Fiorentini F; Forte B; Isacchi A; Martina K; Molinari A; Montagnoli A; Orsini P; Orzi F; Pesenti E; Pezzetta D; Pillan A; Poggesi I; Roletto F; Scolaro A; Tatò M; Tibolla M; Valsasina B; Varasi M; Volpi D; Santocanale C; Vanotti E
    J Med Chem; 2009 Jan; 52(2):293-307. PubMed ID: 19115845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cdc7 kinase complex: a key regulator in the initiation of DNA replication.
    Masai H; Arai K
    J Cell Physiol; 2002 Mar; 190(3):287-96. PubMed ID: 11857444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cdc7 kinase is a predictor of survival and a novel therapeutic target in epithelial ovarian carcinoma.
    Kulkarni AA; Kingsbury SR; Tudzarova S; Hong HK; Loddo M; Rashid M; Rodriguez-Acebes S; Prevost AT; Ledermann JA; Stoeber K; Williams GH
    Clin Cancer Res; 2009 Apr; 15(7):2417-25. PubMed ID: 19318489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell division cycle 7 kinase inhibitors: 1H-pyrrolo[2,3-b]pyridines, synthesis and structure-activity relationships.
    Ermoli A; Bargiotti A; Brasca MG; Ciavolella A; Colombo N; Fachin G; Isacchi A; Menichincheri M; Molinari A; Montagnoli A; Pillan A; Rainoldi S; Sirtori FR; Sola F; Thieffine S; Tibolla M; Valsasina B; Volpi D; Santocanale C; Vanotti E
    J Med Chem; 2009 Jul; 52(14):4380-90. PubMed ID: 19555113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cdc7 kinase inhibitors: pyrrolopyridinones as potential antitumor agents. 1. Synthesis and structure-activity relationships.
    Vanotti E; Amici R; Bargiotti A; Berthelsen J; Bosotti R; Ciavolella A; Cirla A; Cristiani C; D'Alessio R; Forte B; Isacchi A; Martina K; Menichincheri M; Molinari A; Montagnoli A; Orsini P; Pillan A; Roletto F; Scolaro A; Tibolla M; Valsasina B; Varasi M; Volpi D; Santocanale C
    J Med Chem; 2008 Feb; 51(3):487-501. PubMed ID: 18201066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of XL413, a potent and selective CDC7 inhibitor.
    Koltun ES; Tsuhako AL; Brown DS; Aay N; Arcalas A; Chan V; Du H; Engst S; Ferguson K; Franzini M; Galan A; Holst CR; Huang P; Kane B; Kim MH; Li J; Markby D; Mohan M; Noson K; Plonowski A; Richards SJ; Robertson S; Shaw K; Stott G; Stout TJ; Young J; Yu P; Zaharia CA; Zhang W; Zhou P; Nuss JM; Xu W; Kearney PC
    Bioorg Med Chem Lett; 2012 Jun; 22(11):3727-31. PubMed ID: 22560567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDC7 kinase phosphorylates serine residues adjacent to acidic amino acids in the minichromosome maintenance 2 protein.
    Cho WH; Lee YJ; Kong SI; Hurwitz J; Lee JK
    Proc Natl Acad Sci U S A; 2006 Aug; 103(31):11521-6. PubMed ID: 16864800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA repair: a reinvigorated therapeutic target.
    Bates SE
    Clin Cancer Res; 2010 Sep; 16(18):4510. PubMed ID: 20823139
    [No Abstract]   [Full Text] [Related]  

  • 14. Synthesis and evaluation of pyrido-thieno-pyrimidines as potent and selective Cdc7 kinase inhibitors.
    Zhao C; Tovar C; Yin X; Xu Q; Todorov IT; Vassilev LT; Chen L
    Bioorg Med Chem Lett; 2009 Jan; 19(2):319-23. PubMed ID: 19071019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Xenopus cdc7 function is dependent on licensing but not on XORC, XCdc6, or CDK activity and is required for XCdc45 loading.
    Jares P; Blow JJ
    Genes Dev; 2000 Jun; 14(12):1528-40. PubMed ID: 10859170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stopping replication, at the beginning.
    Jackson PK
    Nat Chem Biol; 2008 Jun; 4(6):331-2. PubMed ID: 18488006
    [No Abstract]   [Full Text] [Related]  

  • 17. Polo-like kinase 1 inhibitors in mono- and combination therapies: a new strategy for treating malignancies.
    Christoph DC; Schuler M
    Expert Rev Anticancer Ther; 2011 Jul; 11(7):1115-30. PubMed ID: 21806334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of DNA replication during the cell cycle: roles of Cdc7 kinase and coupling of replication, recombination, and repair in response to replication fork arrest.
    Masai H; Arai K
    IUBMB Life; 2000 May; 49(5):353-64. PubMed ID: 10902566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aurora kinase inhibitors.
    Kitzen JJ; de Jonge MJ; Verweij J
    Crit Rev Oncol Hematol; 2010 Feb; 73(2):99-110. PubMed ID: 19369091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of Cdc7/Dbf4 kinase activity affects specific phosphorylation sites on MCM2 in cancer cells.
    Charych DH; Coyne M; Yabannavar A; Narberes J; Chow S; Wallroth M; Shafer C; Walter AO
    J Cell Biochem; 2008 Jun; 104(3):1075-86. PubMed ID: 18286467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.